These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23979203)

  • 1. Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer.
    Noronha V; Patil VM; Joshi A; Prabhash K
    Indian J Cancer; 2013; 50(2):122-7. PubMed ID: 23979203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic weekly paclitaxel in advanced unresectable esophageal cancer.
    Noronha V; Patil V; Bhosale B; Joshi A; Purandare N; Prabhash K
    Indian J Cancer; 2013; 50(2):128-34. PubMed ID: 23979204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
    Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
    BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
    Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.
    Richards DA; Richards P; Bodkin D; Neubauer MA; Oldham F
    Clin Lung Cancer; 2005 Nov; 7(3):215-20. PubMed ID: 16354318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
    Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
    Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
    Ichikawa M; Suzuki R; Kataoka K; Noda Y; Shindoh J; Matsumoto S; Tanikawa Y; Suzuki K; Baba K; Shindo Y; Kondo M; Imaizumi K; Kume H; Hasegawa Y; Takagi K; Taniguchi H
    Lung Cancer; 2010 Sep; 69(3):319-22. PubMed ID: 20053476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
    Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer.
    Carter DL; Garfield D; Hathorn J; Mundis R; Boehm KA; Ilegbodu D; Asmar L; Reynolds C
    Clin Lung Cancer; 2012 May; 13(3):205-13. PubMed ID: 22138037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
    Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
    Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy.
    Juan O; Albert A; Villarroya T; Sánchez R; Casan R; Caranana V; Campos JM; Alberola V
    Neoplasma; 2003; 50(3):204-9. PubMed ID: 12937854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
    Jin F; Zhu H; Shi F; Kong L; Yu J
    Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
    Tanaka H; Taima K; Morimoto T; Tanaka Y; Itoga M; Nakamura K; Hayashi A; Kumagai M; Yasugahira H; Mikuniya M; Okudera K; Takanashi S; Tasaka S
    BMC Cancer; 2017 Oct; 17(1):683. PubMed ID: 29037236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic chemotherapy in advanced oral cancers.
    Patil V; Noronha V; D'cruz AK; Banavali SD; Prabhash K
    J Cancer Res Ther; 2012 Jan; 8 Suppl 1():S106-10. PubMed ID: 22322727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.
    Thongprasert S; Cheewakriangkrai R; Napapan S
    J Med Assoc Thai; 2002 Dec; 85(12):1296-300. PubMed ID: 12678167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.
    Gao G; Chu H; Zhao L; Gui T; Xu Q; Shi J
    Lung Cancer; 2012 Jun; 76(3):380-6. PubMed ID: 22226626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.